Jefferies Reiterates Buy on Vertex Pharma (VRTX) Following Investor Event

Vertex Pharma (VRTX) Announces Positive Longer-Term ORKAMBI + KALYDECO Data in CF Progression Modification

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced the presentation of long-term data demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO (ivacaftor) show the potential to modify the progression of cystic fibrosis (CF). The presentations given at the 30th Annual North American Cystic Fibrosis Conference (NACFC) include final data from the PROGRESS 96-week... More

Vertex Pharma (VRTX) Announces Positive Longer-Term ORKAMBI + KALYDECO Data in CF Progression Modification

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced the presentation of long-term data demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO (ivacaftor) show the potential to modify the progression of cystic fibrosis (CF). The presentations given at the 30th Annual North American Cystic Fibrosis Conference (NACFC) include final data from the PROGRESS 96-week... More

Stifel Positive on Vertex (VRTX) as Triple Combo Moves Forward; PT Trimmed to $108

Stifel analyst Adam Walsh trimmed his price target on Vertex (NASDAQ: VRTX) to $108.00 (from $109.00) but maintained a Buy rating as the triple combo moves forward.

Walsh commented, "At last, Vertex outlined the path forward for its triple combo regimens, removing an overhang on the stock as the competitive landscape heats up with Galapagos/Abbvie (not... More

Pre-Open Stock Movers 10/26: (OGXI) (AKAM) (IRBT) Higher; (EW) (NUVA) (P) (CMG) (AAPL) Lower (more...)

Today's Pre-Open Stock Movers

OncoGenex Pharmaceuticals, Inc. (Nasdq: OGXI) 32.3% HIGHER; announced positive survival results from the final analysis of the Phase 2 Borealis-2 trial of apatorsen in combination with docetaxel treatment that enrolled 200 patients with metastatic bladder cancer whose disease had progressed following first-line platinum-based chemotherapy. Patients who received apatorsen treatment experienced a 20% reduction in risk of death, compared to patients receiving docetaxel alone (HR=.80; 95% CI: 0.65-0.98; p=0.078). The primary analysis was a superiority test of overall survival, performed at a one-sided 0.10 significance level using a stratified log-rank test. The trial was conducted by... More

Vertex Pharma (VRTX): Cutting PT But Fundamentals Continue To Look Good - Jefferies

Jefferies analyst, Brian Abrahams, reiterated his Buy rating on shares of Vertex (NASDAQ: VRTX) but cut his price target to $102 from $105 based on changes to the analyst's DCF.

For the quarter, numbers were in line, but 3Q was highlighted by both next-gen correctors,... More

Vertex Pharma (VRTX): Many Shots on Goal But Uncertain Safety Limits Upside - Leerink

Leerink Partners analyst, Geoffrey Porges, reiterated his Outperform rating on shares of Vertex (NASDAQ: VRTX) but cut his price target to $111 from $112 after the company reported Q3 results but, more importantly, disclosed their long anticipated phase II development plans for their triple combination for the... More

Vertex (VRTX) PT Bumped to $88 at BMO Capital Following Results and Triple Combo Update

BMO Capital analyst Do Kim bumped his price target on Vertex (NASDAQ: VRTX) to $88.00 (from $87.00) following results and the triple combo update but maintained a Market Perform rating.

Kim commented, " Vertex's 3Q16 was generally in line with expectations, as prior comments and revised... More